2024
Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations
Yasin F, Sokol E, Vasan N, Pavlick D, Huang R, Pelletier M, Levy M, Pusztai L, Lacy J, Zhang J, Ross J, Cecchini M. Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations. The Oncologist 2024, oyae259. PMID: 39401325, DOI: 10.1093/oncolo/oyae259.Peer-Reviewed Original ResearchAdvanced colorectal cancerPIK3CA mutationsColorectal cancerPI3K inhibitionPI3K inhibitorsBurden of colorectal cancerActivating mutationsResponse to PI3K inhibitionSensitive to PI3K inhibition.Foundation Medicine databaseMetastatic colorectal cancerClinically relevant mutationsMicrosatellite instability-highPI3K signalingTumor DNAPIK3CA variantsClinical carePIK3CA oncogeneClinical variablesE545KGenomic profilingPIK3CAE542KMedicine DatabasePatientsDevimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study
Philip P, Sahai V, Bahary N, Mahipal A, Kasi A, Lima C, Alistar A, Oberstein P, Golan T, Metges J, Lacy J, Fountzilas C, Lopez C, Ducreux M, Hammel P, Salem M, Bajor D, Benson A, Luther S, Pardee T, Van Cutsem E. Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study. Journal Of Clinical Oncology 2024, 42: 3692-3701. PMID: 39088774, DOI: 10.1200/jco.23.02659.Peer-Reviewed Original ResearchMetastatic pancreatic adenocarcinomaOverall survivalCPI-613Randomized phase III trialTreatment-emergent adverse eventsExperimental armDifficult-to-treat diseaseFavorable performance statusProgression-free survivalTreatment naive patientsFirst-line therapyPhase I studyPhase III trialsMedian OSMetastatic adenocarcinomaIII trialsFirst-linePerformance statusPancreatic adenocarcinomaAdverse eventsDevimistatDay 1Disease progressionControl armPatientsA single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer
Verma N, Johung K, Kortmansky J, Zaheer W, Lacy J, Cecchini M, Stein S, Cheng Y, Lam W, Liu S, Reddy V, Hochster H, Higgins S. A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer. Journal Of Gastrointestinal Oncology 2024, 15: 1050-1059. PMID: 38989411, PMCID: PMC11231844, DOI: 10.21037/jgo-24-23.Peer-Reviewed Original Research
2020
Association of Neoadjuvant Treatment Modality with Negative Margin and Pathologic Downstaging in Patients Undergoing Pancreatic Cancer Resection: A National Cancer Database Analysis
Miccio J, Mokhtech M, Jabbour S, Anker C, Patel T, Park H, Cecchini M, Salem R, Kuntsman J, Stein S, Kortmansky J, Lacy J, Narang A, Herman J, Haddock M, Hallemeier C, Johung K, Jethwa K. Association of Neoadjuvant Treatment Modality with Negative Margin and Pathologic Downstaging in Patients Undergoing Pancreatic Cancer Resection: A National Cancer Database Analysis. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e662. DOI: 10.1016/j.ijrobp.2020.07.1980.Peer-Reviewed Original ResearchThe Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic Cancer
Miccio J, Talcott W, Patel T, Park H, Cecchini M, Salem R, Stein S, Kortmansky J, Lacy J, Johung K, Jethwa K. The Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e31-e32. DOI: 10.1016/j.ijrobp.2020.02.538.Peer-Reviewed Original ResearchNeoadjuvant folfirinox in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis
Buettner S, Janssen Q, Suker M, Beumer B, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali M, Besselink M, Boone B, Chau I, Clarke S, Dillhoff M, El-Rayes B, Frakes J, Grose D, Hosein P, Jamieson N, Javed A, Khan K, Kim K, Kim S, Kim S, Ko A, Lacy J, Margonis G, McCarter M, McKay C, Mellon E, Moorcraft S. Neoadjuvant folfirinox in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis. Hepato Pancreato Biliary 2020, 22: s327. DOI: 10.1016/j.hpb.2020.04.310.Peer-Reviewed Original Research
2019
KRAS mutation and microsatellite instability in colorectal cancer: Screening pattern and mutational landscape across the US.
Uhlig J, Stein S, Lacy J, Kim H. KRAS mutation and microsatellite instability in colorectal cancer: Screening pattern and mutational landscape across the US. Journal Of Clinical Oncology 2019, 37: e15138-e15138. DOI: 10.1200/jco.2019.37.15_suppl.e15138.Peer-Reviewed Original ResearchOverall survivalColorectal cancerKRAS mutationsMicrosatellite instabilityNon-metastatic colorectal cancerPropensity scoreCox proportional hazards modelMetastatic colorectal cancerNational Cancer DatabasePatients' overall survivalProportional hazards modelMutational screeningDistinct mutational patternsPatient ageYounger patientsMutational prevalenceCancer DatabaseCancer factorsCRC siteFemale African AmericansHazards modelAcademic centersEast South CentralPatientsFemale CaucasiansOutcomes for patients with borderline resectable (BR) and locally advanced (LA) pancreatic cancer (PC) treated with induction FOLFIRINOX (FFX) +/- radiation (RT) followed by surgery compared to induction FFX followed by consolidative RT.
Cecchini M, Miccio J, Pahade J, Lacy J, Salem R, Johnson S, Stein S, Kortmansky J, Johung K. Outcomes for patients with borderline resectable (BR) and locally advanced (LA) pancreatic cancer (PC) treated with induction FOLFIRINOX (FFX) +/- radiation (RT) followed by surgery compared to induction FFX followed by consolidative RT. Journal Of Clinical Oncology 2019, 37: 437-437. DOI: 10.1200/jco.2019.37.4_suppl.437.Peer-Reviewed Original Research
2018
662P Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA)
Catenacci D, Park H, Uronis H, Kang Y, Ng M, Gold P, Lacy J, Enzinger P, Park S, Lee K, Yen J, Odegaard J, Franovic A, Baughman J, Muth J, Wynter-Horton A, Wu T, Wigginton J, Davidson-Moncada J, Bang Y. 662P Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA). Annals Of Oncology 2018, 29: viii223. DOI: 10.1093/annonc/mdy282.046.Peer-Reviewed Original ResearchP-320 Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer
Johung K, Kann B, Lacy J, Stein S, Kortmansky J, Zaheer W, Cheng Y, Lam W, Liu S, Decker R, Hochster H, Higgins S. P-320 Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer. Annals Of Oncology 2018, 29: v90. DOI: 10.1093/annonc/mdy151.319.Peer-Reviewed Original ResearchNeoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.
Janssen Q, Buettner S, Suker M, Margonis G, Paniccia A, El-Rayes B, Bahary N, Chau I, Hosein P, Ko A, Lacy J, Jamieson N, Tinchon C, Kim K, Besselink M, Wilmink J, Homs M, van Eijck C, Katz M, Groot Koerkamp B. Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis. Journal Of Clinical Oncology 2018, 36: e16207-e16207. DOI: 10.1200/jco.2018.36.15_suppl.e16207.Peer-Reviewed Original ResearchMORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.
Oh D, Al-Batran S, Chung H, Hollebecque A, Iqbal S, Kim K, Lacy J, Manji G, O'Reilly E, Rahma O, Yoon H, Kwan A, He X, Barak H, Sayyed P, Zhang X, Wang J, Cha E, Bekaii-Saab T. MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer. Journal Of Clinical Oncology 2018, 36: tps4134-tps4134. DOI: 10.1200/jco.2018.36.15_suppl.tps4134.Peer-Reviewed Original ResearchEffect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis.
Shitara K, Shah M, Di Bartolomeo M, Lonardi S, Al-Batran S, Van Cutsem E, Ilson D, Chau I, Alsina M, Lacy J, Takahari D, Sugimoto N, Bendell J, Wainberg Z, Tehfe M, Ferry D, Wei R, Walgren R, Das M, Fuchs C. Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis. Journal Of Clinical Oncology 2018, 36: 4044-4044. DOI: 10.1200/jco.2018.36.15_suppl.4044.Peer-Reviewed Original Research
2017
A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia
Curtis SA, Curtis BR, Lee AI, Hendrickson JE, Lacy J, Podoltsev NA. A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia. Hematology 2017, 23: 429-432. PMID: 29281948, DOI: 10.1080/10245332.2017.1419600.Peer-Reviewed Original ResearchConceptsDrug-induced immune thrombocytopeniaAutoimmune hemolytic anemiaPlatelet-reactive antibodiesImmune thrombocytopeniaThrombotic microangiopathyAdministration of oxaliplatinCycles of FOLFOXOxaliplatin-induced thrombocytopeniaYear old manAnti-RBC IgGEvans syndromeAntibody testingFirst admissionIgM antibodiesSignificant thrombocytopeniaIgG antibodiesHemolytic anemiaThrombocytopeniaLeucovorinPlatelet IgGOlder menOxaliplatinSyndromeBlood centersPatients622PD nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial
Philip P, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Mozo J, Kim E, Dowden S, Zakari A, Borg C, Terrebonne E, Herrero F, Li J, Ong T, Nydam T, Hammel P. 622PD nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial. Annals Of Oncology 2017, 28: v212. DOI: 10.1093/annonc/mdx369.006.Peer-Reviewed Original Research730P Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC)
Portales F, Philip P, Hammel P, Buscaglia M, Pazo-Cid R, Mozo J, Kim E, Dowden S, Zakari A, Borg C, Terrebonne E, Herrero F, Li J, Ong T, Nydam T, Lacy J. 730P Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC). Annals Of Oncology 2017, 28: v248-v249. DOI: 10.1093/annonc/mdx369.114.Peer-Reviewed Original Research
2015
The Yale Gastrointestinal Cancer Biorepository: A comprehensive biospecimen and data resource for studying determinants of pancreatic ductal adenocarcinoma prognosis following curative-intent pancreaticoduodenectomy.
Gould Rothberg BE, Deminie C, Lazowski H, Gibson J, Cha C, Lacy J, Hochster H, Salem R. The Yale Gastrointestinal Cancer Biorepository: A comprehensive biospecimen and data resource for studying determinants of pancreatic ductal adenocarcinoma prognosis following curative-intent pancreaticoduodenectomy. Journal Of Clinical Oncology 2015, 33: 272-272. DOI: 10.1200/jco.2015.33.3_suppl.272.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinomaNeoadjuvant therapyCurative-intent pancreaticoduodenectomyDeterminants of outcomePancreatic ductal adenocarcinoma prognosisPDAC recurrenceMedical comorbiditiesIncident cancerSurgical resectionAdult patientsAdvanced cancerOncology clinicPDAC patientsVital statusGI cancersLifestyle factorsDuctal adenocarcinomaFamily historyPhysical activitySurgical pathologyPDAC prognosisTumor biologyBuffy coatCancerPatients
2014
Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors.
Jhaveri A, Abu-Khalaf M, DiGiovanna M, Pusztai L, Hofstatter E, Sanft T, Sowers N, Lurie B, Silber A, Brandt D, Hochster H, Lacy J, Stein S, Chung G. Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors. Journal Of Clinical Oncology 2014, 32: 2561-2561. DOI: 10.1200/jco.2014.32.15_suppl.2561.Peer-Reviewed Original Research
2005
Phase II trial of docetaxel/irinotecan therapy in metastatic esophageal cancer: evidence for activity in previously untreated patients
Burtness B, Gibson M, Lacy J, Rowen E, Thomas L, Sipples R, McGurk M, Murren J, Forastiere A. Phase II trial of docetaxel/irinotecan therapy in metastatic esophageal cancer: evidence for activity in previously untreated patients. Journal Of Clinical Oncology 2005, 23: 4070-4070. DOI: 10.1200/jco.2005.23.16_suppl.4070.Peer-Reviewed Original Research